These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 15942243)

  • 1. Matrix metalloproteinase-9, its tissue inhibitor(TIMP)-1 and CRP in Alzheimer's disease.
    Inspector M; Aharon-Perez J; Glass-Marmor L; Miller A
    Eur Neurol; 2005; 53(3):155-7. PubMed ID: 15942243
    [No Abstract]   [Full Text] [Related]  

  • 2. [Roles of matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase and hs-CRP in Kawasaki disease].
    Chen R; Zhang AR; Zhao XX; Li ZH
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Dec; 11(12):989-91. PubMed ID: 20113606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
    Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
    Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans.
    Dellalibera-Joviliano R; Jacob-Ferreira AL; Joviliano EE; Tanus-Santos JE; Evora PR
    Vasc Med; 2012 Apr; 17(2):73-8. PubMed ID: 22402936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
    Brunner S; Kim JO; Methe H
    Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum matrix metalloproteinases and tympanosclerosis.
    Aslan H; Başoğlu MS; Sentürk B; Ozbay C; Katilmiş H; Oztürkcan S
    J Laryngol Otol; 2011 Feb; 125(2):142-6. PubMed ID: 20955636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue inhibitors of matrix metalloproteinase-1 levels are increased in serum of patients with allergic contact dermatitis.
    Reduta T; Laudańska H; Laudanski P
    Contact Dermatitis; 2007 Aug; 57(2):100-4. PubMed ID: 17627649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
    Tan J; Hua Q; Xing X; Wen J; Liu R; Yang Z
    Hypertens Res; 2007 Oct; 30(10):959-63. PubMed ID: 18049028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating beta-chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients--role of oxidative stress.
    Pawlak K; Pawlak D; Mysliwiec M
    Cytokine; 2005 Jul; 31(1):18-24. PubMed ID: 15896974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes.
    Lee SW; Song KE; Shin DS; Ahn SM; Ha ES; Kim DJ; Nam MS; Lee KW
    Diabetes Res Clin Pract; 2005 Aug; 69(2):175-9. PubMed ID: 16005367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease.
    Lorenzl S; Albers DS; Relkin N; Ngyuen T; Hilgenberg SL; Chirichigno J; Cudkowicz ME; Beal MF
    Neurochem Int; 2003 Aug; 43(3):191-6. PubMed ID: 12689599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
    Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum or plasma: what kind of blood sample should be used to measure circulating matrix metalloproteinases and their inhibitors?
    Jung K
    J Neuroimmunol; 2005 May; 162(1-2):1-2. PubMed ID: 15833353
    [No Abstract]   [Full Text] [Related]  

  • 16. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.
    Derosa G; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo S; Montagna L; Gravina A; Ferrari I; Galli S; Paniga S; Tinelli C; Cicero AF
    Endothelium; 2006; 13(3):227-31. PubMed ID: 16840178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in perinatal asphyxia.
    Sunagawa S; Ichiyama T; Honda R; Fukunaga S; Maeba S; Furukawa S
    Brain Dev; 2009 Sep; 31(8):588-93. PubMed ID: 18849127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Changes of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in the bronchoalveolar lavage fluid and the serum of patients with idiopathic pulmonary fibrosis].
    Wei LQ; Li ZH; Kang J; Hou XM; Yu RJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Jun; 29(6):399-402. PubMed ID: 17045024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
    Rauvala M; Puistola U; Turpeenniemi-Hujanen T
    Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension.
    Tayebjee MH; Karalis I; Nadar SK; Beevers DG; MacFadyen RJ; Lip GY
    Am J Hypertens; 2005 Mar; 18(3):325-9. PubMed ID: 15797648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.